drugset
drugset / Trial / NCT03352466

NasoShield Study of Safety and Immunogenicity

NCT03352466 ↗

Phase 1 Completed 145 enrolled Altimmune, Inc.
RandomizedSequentialDouble-blindPrevention

Summary

This study is a Phase 1, randomized, double-blind, placebo-controlled, dose-escalation clinical trial to evaluate the safety and immunogenicity of NasoShield in healthy adults 18 to 49 years of age.

Timeline

Start
2018-01-18
Primary completion
2019-05-13
Completion
2019-05-13

Drugs

EvaluationDrugModalityDoseRoute
Comparator BioThrax Vaccine 0.5 ml Subcutaneous
Subject NasoShield Vaccine 1e+08 unknown Intranasal
Subject NasoShield Vaccine 1e+09 unknown Intranasal
Subject NasoShield Vaccine 1e+10 unknown Intranasal
Subject NasoShield Vaccine 1e+11 unknown Intranasal

Indications

No indication recorded.